- Molecular NameGemifloxacin
- SynonymGemifloxacin mesilate; gemifloxacin mesylate
- Weight389.387
- Drugbank_IDDB01155
- ACS_NO175463-14-6
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-0.58
- pka6.4; 9.0
- LogD (pH=7, predicted)-3.09
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.39
- LogSw (predicted, AB/LogsW2.0)0.03
- Sw (mg/ml) (predicted, ACD/Labs)0.15
- No.of HBond Donors3
- No.of HBond Acceptors9
- No.of Rotatable Bonds5
- TPSA121.35
- StatusFDA approved
- AdministrationOral/IV under development
- PharmacologyAn oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed from the gastrointestinal tract.
- Caco_2N/A
- Bioavailability71.0
- Protein binding65.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmLimited metabolism by the liver to minor metabolites
- Half life7 h
- ExcretionFeces (61%); urine (36%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most commonly reported adverse events with a frequency of ≥ 2 % for patients receiving Factive are as follows: diarrhea 5.0%; rash 3.5%; nausea 3.7%; headache 4.2%; abdominal pain 2.2%; vomiting 1.6%; and dizziness 1.7%.
- LD50 (rat)N/A
- LD50 (mouse)N/A